Press release
Gaucher Disease Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Sanofi, Avro Bio, Freeline Therapeutics, Takeda, Pfizer, Genzyme, Actelion, Prevail Therapeutics
To Know in detail about the Gaucher Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gaucher Disease Market Forecast
https://www.delveinsight.com/sample-request/gauchers-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Gaucher Disease Market Report:
• The Gaucher Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• As per Zimran et al. (2022), GD type-specific prevalence estimates per 100,000 population were GD1: 0.26-0.63; GD2 and GD3: 0.02- 0.08 (Europe only); estimates for GD type unspecified or overall ranged 0.11- 139.0/100,000 inhabitants, highest for North America
• According to a study by Oto et al. (2021), the prevalence associated with GD in Japan is lower than that in Western countries (1 per 330,000 vs. 1.16 per 100,000 live births, respectively). In Japan, only ~150 patients were estimated to have GD and the proportion of GD type 1 is rarer than that in other countries
• According to Hughes & Sidransky (2023), type 1 GD (GD1) is the most prevalent type in the United States, Europe, and occurs with greater frequency in the Ashkenazi Jewish population. Type 2 GD (GD2) occurs in all ethnic types
• According to a recent nationwide survey by Sawada et al.(2022), in Japan, the prevalence of GD is estimated to be 1in 530,000, and more than 50% of these patients have GD2 or GD3
• Key Gaucher Disease Companies: Sanofi, Avro Bio, Freeline Therapeutics, Takeda, Pfizer, Genzyme, Actelion, Prevail Therapeutics, Eli Lilly and Company, Amicus Therapeutics, Protalix, ISU Abxis Co., Ltd., and others
• Key Gaucher Disease Therapies: Venglustat, AVR-RD-02, FLT201, velaglucerase alfa, Taliglucerase alfa, Cerezyme®, Imiglucerase, Eliglustat tartrate, ISU302, Miglustat, Methylprednisolone, Sirolimus, afegostat tartrate, PRX-112, and others
• The Gaucher Disease epidemiology based on gender analyzed that females born with GD does not have any family history whereas male child born with GD have family history
• The Gaucher Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gaucher Disease pipeline products will significantly revolutionize the Gaucher Disease market dynamics.
Gaucher Disease Overview
Gaucher Disease is a rare genetic disorder that falls under the category of lysosomal storage diseases. It is caused by mutations in the GBA gene, which encodes an enzyme called glucocerebrosidase. This enzyme is crucial for breaking down a fatty substance called glucocerebroside within lysosomes, the cellular organelles responsible for waste disposal.
When glucocerebroside is not broken down properly, it accumulates in cells, particularly in the liver, spleen, and bone marrow. This accumulation leads to the various symptoms associated with the disease.
Get a Free sample for the Gaucher Disease Market Report:
https://www.delveinsight.com/report-store/gauchers-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Gaucher Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Gaucher Disease Epidemiology Segmentation:
The Gaucher Disease market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Gaucher Disease
• Prevalent Cases of Gaucher Disease by severity
• Gender-specific Prevalence of Gaucher Disease
• Diagnosed Cases of Episodic and Chronic Gaucher Disease
Download the report to understand which factors are driving Gaucher Disease epidemiology trends @ Gaucher Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/gauchers-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Gaucher Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gaucher Disease market or expected to get launched during the study period. The analysis covers Gaucher Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Gaucher Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Gaucher Disease Therapies and Key Companies
• Venglustat: Sanofi
• AVR-RD-02: Avro Bio
• FLT201: Freeline Therapeutics
Discover more about therapies set to grab major Gaucher Disease market share @ Gaucher Disease Treatment Market
https://www.delveinsight.com/sample-request/gauchers-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Gaucher Disease Market Strengths
• Increasing awareness of Gaucher disease
• Advances in the understanding of Gaucher disease pathogenesis
• Pipeline consists of late and early stage candidates.
Gaucher Disease Market Opportunities
• Uptake of potential emerging therapies with better clinical profile expected to be medium-fast due to the present unmet needs
• Several organizations are actively working to provide information and increase awareness of such disorders
Scope of the Gaucher Disease Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Gaucher Disease Companies: Sanofi, Avro Bio, Freeline Therapeutics, Takeda, Pfizer, Genzyme, Actelion, Prevail Therapeutics, Eli Lilly and Company, Amicus Therapeutics, Protalix, ISU Abxis Co., Ltd., and others
• Key Gaucher Disease Therapies: Venglustat, AVR-RD-02, FLT201, velaglucerase alfa, Taliglucerase alfa, Cerezyme®, Imiglucerase, Eliglustat tartrate, ISU302, Miglustat, Methylprednisolone, Sirolimus, afegostat tartrate, PRX-112, and others
• Gaucher Disease Therapeutic Assessment: Gaucher Disease current marketed and Gaucher Disease emerging therapies
• Gaucher Disease Market Dynamics: Gaucher Disease market drivers and Gaucher Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Gaucher Disease Unmet Needs, KOL's views, Analyst's views, Gaucher Disease Market Access and Reimbursement
To know more about Gaucher Disease companies working in the treatment market, visit @ Gaucher Disease Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/gauchers-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Gaucher Disease Market Report Introduction
2. Executive Summary for Gaucher Disease
3. SWOT analysis of Gaucher Disease
4. Gaucher Disease Patient Share (%) Overview at a Glance
5. Gaucher Disease Market Overview at a Glance
6. Gaucher Disease Disease Background and Overview
7. Gaucher Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Gaucher Disease
9. Gaucher Disease Current Treatment and Medical Practices
10. Gaucher Disease Unmet Needs
11. Gaucher Disease Emerging Therapies
12. Gaucher Disease Market Outlook
13. Country-Wise Gaucher Disease Market Analysis (2019-2032)
14. Gaucher Disease Market Access and Reimbursement of Therapies
15. Gaucher Disease Market Drivers
16. Gaucher Disease Market Barriers
17. Gaucher Disease Appendix
18. Gaucher Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Gaucher Disease Epidemiology https://www.delveinsight.com/report-store/gauchers-disease-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Gaucher Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Gaucher Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Bacterial Vaginosis Market
https://www.delveinsight.com/report-store/bacterial-vaginosis-market
DelveInsight's comprehensive report titled "Bacterial Vaginosis Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of bacterial vaginosis. The report presents historical and projected epidemiological data covering Total Prevalent Cases and Diagnosed Prevalent Cases of Bacterial vaginosis further segmented by Age.
Bile Duct Cancer Market
DelveInsight's "Bile Duct Cancer Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Bile Duct Cancer, historical and forecasted epidemiology as well as the Bile Duct Cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom and Japan.
Egfr-induced Skin Disorders Market
https://www.delveinsight.com/report-store/egfr-inhibitors-induced-skin-disorders-market
DelveInsight's "EGFR Inhibitors-Induced Skin Disorders Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of EGFR Inhibitors-Induced Skin Disorders, historical and forecasted epidemiology as well as the EGFR Inhibitors-Induced Skin Disorders market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Endometrial Cancer Market
https://www.delveinsight.com/report-store/endometrial-cancer-market
DelveInsight's "Endometrial Cancer Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Endometrial Cancer, historical and forecasted epidemiology as well as the Endometrial Cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom and Japan.
Fragile X Syndrome Market
https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-market
DelveInsight's "Fragile X Syndrome (FXS) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Fragile X Syndrome (FXS), historical and forecasted epidemiology as well as the Fragile X Syndrome (FXS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gaucher Disease Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Sanofi, Avro Bio, Freeline Therapeutics, Takeda, Pfizer, Genzyme, Actelion, Prevail Therapeutics here
News-ID: 3642861 • Views: …
More Releases from DelveIinsight Business Research
Thymidine Kinase 2 Deficiency Market Insights: Unmet Needs and Emerging Therapie …
The Thymidine Kinase 2 deficiency (TK2d) market is poised for substantial growth in the coming decade, fueled by increasing awareness of this rare genetic disorder and the development of promising therapies like MT1621 (UCB).
DelveInsight's "Thymidine Kinase 2 Deficiency Market Insight, Epidemiology and Market Forecast - 2034" report delivers comprehensive insights into the current TK2d landscape and future market trends across the 7MM (United States, EU4, the United Kingdom, and Japan).…
Pigment Epithelial Detachment Market Outlook: Aging Population, AI-Driven Diagno …
Recent analysis by DelveInsight indicates that the retinal pigment epithelium market is poised for notable growth, with the 7MM expected to achieve a respectable CAGR. This growth is being fueled by several factors, including an aging population, advancements in AI-driven diagnosis, industry collaborations, and novel therapeutic options. Key retinal pigment epithelium companies include Sumitomo Pharma, Healios K.K., Eyestem Research, Luxa Biotechnology, Regenerative Patch Technologies, Lineage Cell Therapeutics, Katairo GmbH, Visgenx…
Chronic Obstructive Pulmonary Disease Market Forecast 2024-2034: Competitive Int …
The chronic obstructive pulmonary disease (COPD) market is projected to experience steady growth in the coming years, driven primarily by increasing diagnosed prevalent cases and the introduction of novel biologics and combination therapies by key COPD companies, including Sanofi, Regeneron Pharmaceuticals, GlaxoSmithKline, AstraZeneca, and Amgen, among others. This market expansion reflects advancements in targeted therapeutic approaches, particularly for patients with specific phenotypes, improved diagnostic capabilities, and rising awareness among healthcare…
Blastic Plasmacytoid Dendritic Cell Neoplasm Treatment Landscape Transforms with …
The Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market across the 7MM is poised for significant growth through 2034. This growth is driven by advancements in targeted therapies, increased awareness of the disease among healthcare professionals, and ongoing research and development efforts. Major pharmaceutical and biotech companies, including AbbVie, ImmunoGen, Mustang Bio, Genentech, Stemline Therapeutics, Jazz Pharmaceuticals, Menarini Group, Cellex Patient Treatment GmbH, and Xencor, are actively engaged in the BPDCN…
More Releases for Gaucher
Gaucher & Pompe Diseases Enzyme Replacement Therapy (ERT) Market - Restoring Bal …
Newark, New Castle, USA: The "Gaucher & Pompe Diseases Enzyme Replacement Therapy (ERT) Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Gaucher & Pompe Diseases Enzyme Replacement…
Gaucher Disease Treatment Market Size | Share | Growth Analysis 2022
The global gaucher disease treatment market size was valued at USD 1,522.3 million in 2021 and is poised to grow at a significant CAGR of 1.2% during the forecast period 2022-28. Gaucher disease is a rare genetic disorder that affects the body's ability to break down a certain type of fat called glucocerebroside. This build-up of fat can cause a range of symptoms, including enlarged organs, bone pain, anemia, and…
Gaucher Disease Treatment Market Size | Share | Growth Analysis 2022
The global gaucher disease treatment market size was valued at USD 1,522.3 million in 2021 and is poised to grow at a significant CAGR of 1.2% during the forecast period 2022-28. Gaucher disease is a rare genetic disorder that affects the body's ability to break down a certain type of fat called glucocerebroside. This build-up of fat can cause a range of symptoms, including enlarged organs, bone pain, anemia, and…
Gaucher Disease Market Revenue Data Historic and Forecast Analysis
The market for Gaucher disease was estimated at USD 980.0 million in 2021, and it is anticipated to grow at a CAGR of 8.5% to reach around USD 1,800.0 million in 2029.
The rising prevalence of Gaucher disease, increasing awareness about Gaucher disease, and upsurge in the number of approved therapies for the treatment of Gaucher disease. Even it is the most prevalent lysosomal storage disorder, Gaucher disease is a rare…
Global Gaucher Disease Drugs Market Size – Forecast to 2026
The findings reviewed by GME stated that the Global Gaucher Disease Drugs Market will expand with a CAGR value of 2.1 percent from 2021 to 2026. The Gaucher disease treatment demand is primarily influenced by factors like the rising incidence of disease in both men and women of all ages and the resulting rise in the number of medications available in the marketplace. Also, a growing number of major players…
Gaucher Disease Market Size by 2025: QY Research
This recently published report examines the global Gaucher Disease market for the projected period of 7-years, i.e. between 2018 and 2025. The report highlights the accomplishments and opportunities lies in the market throughout the forecasted period. The report offers the thorough information about the overview and the scope of the global Gaucher Disease market along with its drivers, restraints, and trends. It also classifies the market into different segments such…
